- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05416619
Effects of Hand MOtor Rehabilitation Using a sEMG-biofeedback (MORE)
Effects of Hand MOtor Rehabilitation Using a sEMG-biofeedback, After Stroke: a Longitudinal Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim of the study is to investigate the effect of using REMO® (Morecognition srl, Turin, Italy) device in hand motor rehabilitation.
The device REMO® is an armband composed by 8 bipolar electrodes able to record and process the electromyography of forearm muscles. The patterns of muscle activations are classified and used to perform sEMG-biofeedback exercises in stroke rehabilitation training. The device is developed by clinicians of IRCCS San Camillo Hospital and Morecognition Srl.
A total of 20 patients with first diagnosis of stroke and with no other neurological diagnosis or severe cognitive impairment has been enrolled. The patients are tested with REMO® and if they are able to control at least one movements, they are enrolled in the longitudinal pilot study. The treatment consists in 15 sessions, 1hour/day, for 5 days/week, for 3 weeks. The patients are clinically evaluated before and after the REMO® treatment to define clinical effect of the sEMG-biofeedback training.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Venice
-
Venice-Lido, Venice, Italy, 30126
- IRCCS San Camillo Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Single ischemic or haemorrhagic stroke
- able to control at least 1 movement with REMO (i.e. able to cross the pre-defined empirical threshold (10%) of the ratio between the maximum voluntary contraction (MVC) of the movement and the EMG recording during baseline (i.e. rest position)
Exclusion Criteria:
- Untreated epilepsy;
- Major depressive disorder;
- Fractures;
- Traumatic Brain Injury;
- Severe Ideomotor Apraxia;
- Severe Neglect;
- Severe impairment of verbal comprehension.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: sEMG-biofeedback Group
Receive 1 hour of sEMG-biofeedback hand training provided by wearable REMO® and 1 hour of daily conventional rehabilitation therapy.
|
The patients receive daily 1 hour of conventional therapy and 1 hour of treatment of REMO®, that is a wearable composed by 8 bipolar electrodes able to detect the surface electromyography of the forearm muscles.
REMO® allows the control of a computer interface using the surface electromyography to execute sEMG-biofeedback exercises for hand rehabilitation.
The movements required for hand rehabilitation are the following: thumb abduction, pinch, finger flexion, finger extension, wrist flexion, wrist extension, forearm pronation, forearm supination, radial wrist deviation and ulnar wrist deviation.
The treatment consists in 15 sessions, 1hour/day, for 5 days/week, for 3 weeks.
The patients are clinically evaluated before and after the REMO® treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fugl-Meyer Upper Extremity
Time Frame: Change from baseline, at 3 weeks (15 sessions).
|
Fugl-Meyer Upper Extremity is a stroke-specific scale which assesses the upper limb motor functioning in patients with post-stroke hemiplegia.
There are 3 values: 0 (severe impairment), 1 (moderate impairment), 2 (preserved function).
The minimum value is 0 points, which corresponds to upper limb hemiplegia.
The maximum value is 66 points, which corresponds to normal motor performance.
|
Change from baseline, at 3 weeks (15 sessions).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fugl-Meyer - sensation
Time Frame: Change from baseline, at 3 weeks (15 sessions).
|
Sensation of the hemiparetic side is measured by means of the Fugl-Meyer Scale.
There are 3 values: 0 (severe impairment), 1 (moderate impairment), 2 (preserved function).
The minimum value is 0 points, which corresponds to completely impaired sensory functioning.
The maximum value is 24 points, which corresponds to normal sensory functioning.
|
Change from baseline, at 3 weeks (15 sessions).
|
|
Fugl-Meyer - pain and Range of Motion
Time Frame: Change from baseline, at 3 weeks (15 sessions).
|
Pain and Range of Motion of the hemiparetic upper limb is measured by means of the Fugl-Meyer Scale.
There are 3 values: 0 (severe impairment), 1 (moderate impairment), 2 (preserved function).
The minimum value is 0 points, which corresponds to maximum level of pain and restriction.
The maximum value is 48 points, which corresponds to no pain and normal range of motion.
|
Change from baseline, at 3 weeks (15 sessions).
|
|
Box and Blocks Test
Time Frame: Change from baseline, at 3 weeks (15 sessions).
|
The patient has to carry as much cubes as possible, one by one, from a container to another one in one minute.
The test is performed with both hands.
|
Change from baseline, at 3 weeks (15 sessions).
|
|
Reaching Performance Scale
Time Frame: Change from baseline, at 3 weeks (15 sessions).
|
Reaching Performance Scale assesses the ability of subjects to reach an object (a cone).
The cone is placed at both 4-cm (close) and 30-cm (far) distance from the subject.
The subject is asked to reach and grab the cone if possible.
The observer evaluates the quality of reaching instead of the grip strength.
The minimum value is 0 points, which corresponds to incapacity of any ability of reaching an object.
The maximum value is 36 points, which corresponds to the preservation of the ability of reaching an object.
|
Change from baseline, at 3 weeks (15 sessions).
|
|
Modified Ashworth Scale
Time Frame: Change from baseline, at 3 weeks (15 sessions).
|
Spasticity is measured using the Modified Ashworth Scale of five muscles: Pectoralis major, biceps, wrist flexors, flexor digitorum superficialis, flexor digitorum profundus (Total score = 20 points).
The therapist evaluates the spasticity of each muscles.
There are 5 values: 0 (no increase in muscle tone), 1 (slight increase in muscle tone), 2 (more marked increase in muscle tone), 3 (considerable increase in muscle tone), 4 (affected part rigid in flexion or extension).
|
Change from baseline, at 3 weeks (15 sessions).
|
|
Nine Hole Pegboard Test
Time Frame: Change from baseline, at 3 weeks (15 sessions).
|
Nine Hole Pegboard Test measures the dexterity of the hand.
Patient should insert 9 pins in the board.
There are 9 pins.
The number of pins inserted in 50 sec are registered or if the patient inserted 9 pins, then the time is registered.
|
Change from baseline, at 3 weeks (15 sessions).
|
|
Functional Independence Measure
Time Frame: Change from baseline, at 3 weeks (15 sessions).
|
Functional Independence Measure scale is an 18-item scale that assesses the degree of independence in carrying out activities of daily living.
There are 7 values: 1 (Total Assistance or not Testable), 2 (Maximal Assistance), 3 (Moderate Assistance), 4 (Minimal Assistance), 5 (Supervision), 6 (Modified Independence), 7 (Complete Independence).
The minimum values is 18 points, which corresponds to the lower level of independence in activities of daily living.
The maximum value is 126 points, which corresponds to the maximum level of independence in activities of daily living.
|
Change from baseline, at 3 weeks (15 sessions).
|
|
Number of movements controlled by REMO® device
Time Frame: Change from baseline, at 3 weeks (15 sessions).
|
The patient is able to control a movement with the device if he crosses the pre-defined empirical threshold (10%) of the ratio between the maximum voluntary contraction (MVC) of the movement and the sEMG recording during baseline (i.e.
rest position).
|
Change from baseline, at 3 weeks (15 sessions).
|
Collaborators and Investigators
Investigators
- Principal Investigator: Andrea Turolla, PhD, IRCCS San Camillo Hospital
Publications and helpful links
General Publications
- Celadon N, Dosen S, Binder I, Ariano P, Farina D. Proportional estimation of finger movements from high-density surface electromyography. J Neuroeng Rehabil. 2016 Aug 4;13(1):73. doi: 10.1186/s12984-016-0172-3.
- Paleari M, Di Girolamo M, Celadon N, Favetto A, Ariano P. On optimal electrode configuration to estimate hand movements from forearm surface electromyography. Annu Int Conf IEEE Eng Med Biol Soc. 2015;2015:6086-9. doi: 10.1109/EMBC.2015.7319780.
- Di Girolamo M, Celadon N, Appendino S, Turolla A. and Ariano P. EMG-based biofeedback system for motor rehabilitation: A pilot study,. IEEE Biomedical Circuits and Systems Conference (BioCAS). 2017; pp. 1-4, doi: 10.1109/BIOCAS.2017.8325086.
- Parker J, Powell L, Mawson S. Effectiveness of Upper Limb Wearable Technology for Improving Activity and Participation in Adult Stroke Survivors: Systematic Review. J Med Internet Res. 2020 Jan 8;22(1):e15981. doi: 10.2196/15981.
- Maceira-Elvira P, Popa T, Schmid AC, Hummel FC. Wearable technology in stroke rehabilitation: towards improved diagnosis and treatment of upper-limb motor impairment. J Neuroeng Rehabil. 2019 Nov 19;16(1):142. doi: 10.1186/s12984-019-0612-y.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016.29.1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
National Assembly ClinicBayero University Kano, NigeriaRecruitingStroke | Stroke Hemorrhagic | Stroke Ischemic | Hemiparesis After StrokeNigeria
-
University of PittsburghRecruitingHemorrhagic Stroke | Embolic Stroke of Undetermined Source | Ischemic Stroke, Cryptogenic | Recurrent Ischemic Stroke | Ischemic Stroke, EmbolicUnited States
-
Mahidol UniversityNot yet recruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke SurvivorsThailand
-
Mahidol UniversityRecruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke PatientThailand
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
Fondazione Don Carlo Gnocchi OnlusScuola Superiore Sant'Anna di Pisa; Fondazione Policlinico Universitario Campus...Not yet recruitingStroke | Stroke Hemorrhagic | Upper Limb Rehabilitation | Stroke IschemicItaly
-
Samsung Medical CenterCompletedChronic Stroke | Subacute Stroke | ExoskeletonSouth Korea
-
University of Illinois at ChicagoRecruitingStroke, Ischemic | Stroke Hemorrhagic | Stroke, CerebrovascularUnited States
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
Clinical Trials on REMO®
-
Orion Corporation, Orion PharmaCompleted
-
Orion Corporation, Orion PharmaCompletedCerumen Impaction of Both EarsLithuania
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
IRCCS San Camillo, Venezia, ItalyCompletedStroke | Hemiplegia | Stroke, Ischemic | Stroke Hemorrhagic | HemiparesisItaly
-
Beth Israel Medical CenterCompletedSepsis | Prematurity | RDS | SGA
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
Chong Kun Dang PharmaceuticalCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Diphtheria | PolioUnited States
-
Chung-Ang University Hosptial, Chung-Ang University...UnknownFunctional DyspepsiaKorea, Republic of